Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.35 USD
Change Today 0.00 / 0.00%
Volume 0.0
POLXF On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 07/29/15 All times are local (Market data is delayed by at least 15 minutes).

polydex pharmaceuticals ltd (POLXF) Snapshot

Open
$1.35
Previous Close
$1.35
Day High
$1.35
Day Low
$1.35
52 Week High
07/21/15 - $1.49
52 Week Low
11/10/14 - $0.66
Market Cap
4.1M
Average Volume 10 Days
680.0
EPS TTM
$0.13
Shares Outstanding
3.1M
EX-Date
--
P/E TM
10.2x
Dividend
--
Dividend Yield
--
Current Stock Chart for POLYDEX PHARMACEUTICALS LTD (POLXF)

Related News

No related news articles were found.

polydex pharmaceuticals ltd (POLXF) Related Businessweek News

No Related Businessweek News Found

polydex pharmaceuticals ltd (POLXF) Details

Polydex Pharmaceuticals Limited, through its subsidiaries, develops, manufactures, and markets biotechnology-based products for the human pharmaceutical market; and manufactures bulk pharmaceutical intermediates for the veterinary pharmaceutical industry worldwide. The company primarily offers Dextran and derivative products, including Iron Dextran, a derivative of Dextran used for the treatment of anemia in pigs; and Dextran Sulphate, a specialty chemical derivative of Dextran used in research applications by the pharmaceutical industry and other centers of chemical research. Polydex Pharmaceuticals Limited company sells its Iron Dextran primarily to independent distributors and wholesalers in Europe, the Far East, South America, and Canada; and Dextran Sulphate to the independent distributors and wholesalers in the United States and Europe for analytical applications. It also develops Ushercell, a high molecular weight Cellulose Sulphate envisioned for topical vaginal use primarily in the prevention and transmission of AIDS and other sexually transmitted diseases, as well as unplanned pregnancies; and Usherdex 4 for the treatment of Cystic fibrosis, a genetic disease. The company was formerly known as Polydex Chemicals Limited and changed its name to Polydex Pharmaceuticals Limited in March 1984. Polydex Pharmaceuticals Limited was founded in 1966 and is based in Toronto, Canada.

21 Employees
Last Reported Date: 04/30/15
Founded in 1966

polydex pharmaceuticals ltd (POLXF) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

polydex pharmaceuticals ltd (POLXF) Key Developments

Polydex Pharmaceuticals Limited Reports Financial Results for the First Quarter Ended April 30, 2015

Polydex Pharmaceuticals Limited reported financial results for the first quarter ended April 30, 2015. For the quarter, the company reported sales of $1,561,177 against $1,412,982 a year ago. Net income was $319,727 or 40.09 per diluted share against $74,595 or $0.02 per diluted share a year ago. Profit increased compared to the first quarter of fiscal 2015 due to an increase in powdered product sales. This was facilitated by minimal production breakdowns, which in turn resulted primarily from the significant investment in equipment in previous periods. EBITDA (Earnings before interest, taxes, depreciation and amortization) for the three months ended April 30, 2015 amounts to $368,505, a significant increase over the same period last year of $120,875.

Polydex Pharmaceuticals Limited Announces Earnings Results for Year and Sales Results for the Fourth Quarter Ended January 31, 2015

Polydex Pharmaceuticals Limited announced earnings results for year and sales results for the fourth quarter ended January 31, 2015. For the year, the company reported sales of USD 5,376,027 against USD 5,963,784 a year ago. Net income was USD 578,212 against USD 658,922 a year ago. Diluted income per common share was USD 0.16 against USD 0.20 a year ago. EBITDA amounted to USD 796,268. For the fourth quarter, sales were USD 1,391,739, representing an increase of nearly 4% over the same period in the previous year. Sales decreased slightly from last year due to installation of new equipment.

Polydex Pharmaceuticals Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2014

Polydex Pharmaceuticals Ltd. reported earnings results for the third quarter and nine months ended October 31, 2014. For the quarter, the company reported sales of $1,301,083 against $1,319,100 a year ago. Net income was $104,653 or $0.03 per basic and diluted share against net income of $46,300 or $0.01 per basic and diluted share a year ago. EBITDA (Earnings before interest, taxes, depreciation and amortization) increased to $183,944 compared to $93,669 for the same period in the previous year. For the nine months, the company reported sales of $3,984,288 against $4,625,497 a year ago. Net income was $238,388 or $0.07 per diluted share against net income of $518,594 or $0.15 per diluted share a year ago. EBITDA was $416,348.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
POLXF:US $1.35 USD 0.00

POLXF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for POLXF.
View Industry Companies
 

Industry Analysis

POLXF

Industry Average

Valuation POLXF Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact POLYDEX PHARMACEUTICALS LTD, please visit www.polydex.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.